Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort
Open Access
- 16 January 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (1), e0209605
- https://doi.org/10.1371/journal.pone.0209605
Abstract
The prevalence of transmitted drug resistance (TDR) in antiretroviral therapy (ART)-naïve individuals remains stable in most developed countries despite a decrease in the prevalence of acquired drug resistance. This suggests that persistence and further transmission of HIV-1 that encodes transmitted drug resistance mutations (TDRMs) is occurring in ART-naïve individuals. In this study, we analysed the prevalence and persistence of TDRMs in the protease and reverse transcriptase-sequences of ART-naïve patients within the German HIV-1 Seroconverter Study Cohort who were infected between 1996 and 2017. The prevalence of TDRMs and baseline susceptibility to antiretroviral drugs were assessed using the Stanford HIVdb list and algorithm. Mean survival times of TDRMs were calculated by Kaplan-Meier analysis. The overall prevalence of TDR was 17.2% (95% CI 15.7–18.6, N = 466/2715). Transmitted NNRTI resistance was observed most frequently with 7.8% (95% CI 6.8–8.8), followed by NRTI resistance (5.0%, 95% CI 4.2–5.9) and PI resistance (2.8%, 95% CI 2.2–3.4). Total TDR (OR = 0.89, p = 0.034) and transmitted NRTI resistance (OR = 0.65, p = 0.000) decreased between 1996 and 2017 but has remained stable during the last decade. Viral susceptibility to NNRTIs (6.5%-6.9% for individual drugs) was mainly reduced, while <3% of the recommended NRTIs and PIs were affected. The longest mean survival times were calculated for the NNRTI mutations K103N (5.3 years, 95% CI 4.2–5.6) and E138A/G/K (8.0 years, 95% CI 5.8–10.2 / 7.9 years, 95% CI 5.4–10.3 / 6.7 years, 95% CI 6.7–6.7) and for the NRTI mutation M41L (6.4 years, 95% CI 6.0–6.7).The long persistence of single TDRMs indicates that onward transmission from ART-naïve individuals is the main cause for TDR in Germany. Transmitted NNRTI resistance was the most frequent TDR, showing simultaneously the highest impact on baseline ART susceptibility and on TDRMs with prolonged persistence. These results give cause for concern regarding the use of NNRTI in first-line regimens.Keywords
This publication has 59 references indexed in Scilit:
- Basis for Early and Preferential Selection of the E138K Mutation in HIV-1 Reverse TranscriptaseAntimicrobial Agents and Chemotherapy, 2013
- Persistence of HIV-1 Transmitted Drug Resistance MutationsThe Journal of Infectious Diseases, 2013
- Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation ClassesThe Journal of Infectious Diseases, 2011
- Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter CohortPLOS ONE, 2010
- Detection of Human Immunodeficiency Virus (HIV) Type 1 M184V and K103N Minority Variants in Patients with Primary HIV InfectionAntimicrobial Agents and Chemotherapy, 2009
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLOS ONE, 2009
- Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus InfectionJournal of Virology, 2008
- Episodic Sexual Transmission of HIV Revealed by Molecular PhylodynamicsPLoS Medicine, 2008
- The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational InteractionsJournal of Virology, 2007
- Rationale and Uses of a Public HIV Drug‐Resistance DatabaseThe Journal of Infectious Diseases, 2006